These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 12710884)

  • 41. B-type natriuretic peptide for the treatment of congestive heart failure.
    Schreiner GF; Protter AA
    Curr Opin Pharmacol; 2002 Apr; 2(2):142-7. PubMed ID: 11950624
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of natriuretic peptides in cGMP production in fetal cardiac bypass.
    Heeb EA; Baker RS; Lam C; Basu M; Lubbers W; Duffy JY; Eghtesady P
    Ann Thorac Surg; 2009 Mar; 87(3):841-7. PubMed ID: 19231402
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Atrial natriuretic peptides: a new diagnostic tool for the internist].
    Boari B; Manfredini R; Fellin R
    Recenti Prog Med; 2005 Jun; 96(6):300-10. PubMed ID: 16078761
    [TBL] [Abstract][Full Text] [Related]  

  • 44. From B-type natriuretic peptide to green mambas: the process of discovery.
    Francis GS
    J Am Coll Cardiol; 2008 Jul; 52(1):69-70. PubMed ID: 18582637
    [No Abstract]   [Full Text] [Related]  

  • 45. Diagnosis of heart failure using urinary natriuretic peptides.
    Ng LL; Geeranavar S; Jennings SC; Loke I; O'Brien RJ
    Clin Sci (Lond); 2004 Feb; 106(2):129-33. PubMed ID: 13678415
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Natriuretic cardiac hormones. Clinical use in heart failure].
    Nielsen SJ; Gøtze JP; Raymond IE; Grønning BA; Kirk V; Bay-Nielsen M; Hildebrandt PR; Aldershvile J
    Ugeskr Laeger; 2004 Jan; 166(4):248-53. PubMed ID: 14964102
    [No Abstract]   [Full Text] [Related]  

  • 47. Discovery of new cardiovascular hormones for the treatment of congestive heart failure.
    Vesely DL
    Cardiovasc Hematol Disord Drug Targets; 2007 Mar; 7(1):47-62. PubMed ID: 17346128
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Newer approaches to the pharmacological management of heart failure.
    Rauch H; Motsch J; Böttiger BW
    Curr Opin Anaesthesiol; 2006 Feb; 19(1):75-81. PubMed ID: 16547437
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure.
    Davis ME; Richards AM; Nicholls MG; Yandle TG; Frampton CM; Troughton RW
    Circulation; 2006 Feb; 113(7):977-85. PubMed ID: 16476851
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Beneficial effects of early initiation of vasoactive agents in patients with acute decompensated heart failure.
    Saltzberg MT
    Rev Cardiovasc Med; 2004; 5 Suppl 4():S17-27. PubMed ID: 15627915
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vasodilator therapy for decompensated heart failure.
    Yancy CW
    J Am Coll Cardiol; 2008 Jul; 52(3):208-10. PubMed ID: 18617069
    [No Abstract]   [Full Text] [Related]  

  • 52. Evolution of amino-terminal pro-B type natriuretic peptide testing in heart failure.
    Januzzi JL; Bayes-Genis A
    Drug News Perspect; 2009 Jun; 22(5):267-73. PubMed ID: 19609464
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Drug discovery for heart failure: a new era or the end of the pipeline?
    Kaye DM; Krum H
    Nat Rev Drug Discov; 2007 Feb; 6(2):127-39. PubMed ID: 17268484
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Increased susceptibility to heart failure in response to volume overload in mice lacking natriuretic peptide receptor-A gene.
    Nishikimi T; Hagaman JR; Takahashi N; Kim HS; Matsuoka H; Smithies O; Maeda N
    Cardiovasc Res; 2005 Apr; 66(1):94-103. PubMed ID: 15769452
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases.
    Rubattu S; Sciarretta S; Valenti V; Stanzione R; Volpe M
    Am J Hypertens; 2008 Jul; 21(7):733-41. PubMed ID: 18464748
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dysfunction of atrial and B-type natriuretic peptides in congenital univentricular defects.
    Sun LS; Dominguez C; Mallavaram NA; Quaegebeur JM
    J Thorac Cardiovasc Surg; 2005 May; 129(5):1104-10. PubMed ID: 15867787
    [TBL] [Abstract][Full Text] [Related]  

  • 57. B-type natriuretic peptide in heart failure.
    Moe GW
    Curr Opin Cardiol; 2006 May; 21(3):208-14. PubMed ID: 16601459
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of nesiritide (human b-type natriuretic peptide) and dobutamine on heart rate variability in decompensated heart failure.
    Aronson D; Burger AJ
    Am Heart J; 2004 Nov; 148(5):e16. PubMed ID: 15523294
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Physiologic and pathophysiologic effects of natriuretic peptides and their implications in cardiopulmonary disease.
    Turk JR
    J Am Vet Med Assoc; 2000 Jun; 216(12):1970-6. PubMed ID: 10863599
    [No Abstract]   [Full Text] [Related]  

  • 60. USAN Council. List No.440. New names. Nesiritide citrate.
    Clin Pharmacol Ther; 2001 Aug; 70(2):200. PubMed ID: 11558466
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.